GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
+0.50 (+2.45%)
At close: 11:24AM EDT
Stock chart is not supported by your current browser
Previous close20.39
Bid0.00 x 0
Ask0.00 x 0
Day's range20.35 - 20.89
52-week range18.14 - 21.20
Avg. volume1,854
Market cap105.323B
Beta (3Y monthly)0.54
PE ratio (TTM)42.12
Earnings dateN/A
Forward dividend & yield0.95 (4.66%)
Ex-dividend date2019-05-16
1y target estN/A
Trade prices are not sourced from all markets
Press releases
  • Business Wire9 days ago

    ViiV Healthcare Announces Phase III Study Meets Primary Endpoint, Demonstrating the Ability to Control HIV-1 With the 2-drug Regimen Dovato (dolutegravir Plus Lamivudine) in Virally Suppressed Patients Switching From a TAF-containing, 3-drug Regimen

    LONDON--(BUSINESSWIRE)-- ViiV Healthcare , the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from ...

  • Business Wire16 days ago

    ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

    Deborah Waterhouse, CEO, ViiV Healthcare, said: “For many years, the standard of care for treatment-naïve people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals. With around 25,000 new HIV diagnoses in Europe* every year2, and the fact that today HIV is considered a chronic condition which requires people living with HIV (PLHIV) to remain on antiretroviral (ARV) treatment for life, it is ever more important to provide innovative treatment options.

  • Business Wirelast month

    Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options

    GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.

  • Business Wire3 months ago

    Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

    LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple ...

  • Business Wire7 months ago

    Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company

    Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.

  • Business Wire8 months ago

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • Business Wire10 months ago

    Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes